# US 2012/0252724 A1 · Insulin preparations containing methionine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252724 A1
- Document ID: US20120252724A1
- Status: Published application
- Kind: A1
- Application number: 13/382,442
- Filed: 2010-07-02
- Published: 2012-10-04
- Earliest claimed: 2009-07-06
- Assignees: Sanofi-Aventis
- Inventors: Isabell Schoettle; Annika Hagendorf; Christiane Fuerst; Gerrit Hauck; Verena Siefke-Henzler; Walter Kamm; Julia Schnieders
- Web page: https://patentgrep.com/patent/US20120252724A1

## CPC

- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/10: Dispersions; Emulsions
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 38/2278: {Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)}
- A61K 38/26: Glucagons
- A61K 38/28: Insulins
- A61K 47/00: Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 47/20: containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/08: for glucose homeostasis (pancreatic hormones A61P5/48)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/48: of the pancreatic hormones
- A61P 5/50: for increasing or potentiating the activity of insulin
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/62: Insulins
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The invention relates to an aqueous pharmaceutical formulation having insulin, an insulin analog, or an insulin derivative, and methionine; and to the production thereof, to the use thereof for treating diabetes mellitus, and to a medication for treating diabetes mellitus.

## Claims

### Claim 1

An aqueous pharmaceutical formulation comprising an insulin, insulin analog or insulin derivative, or a pharmacologically tolerable salt thereof, and methionine.

### Claim 2 (depends on 1)

The pharmaceutical formulation as claimed in claim 1, the insulin being selected from the group consisting of human insulin, porcine insulin, and bovine insulin.

### Claim 3 (depends on 1)

The pharmaceutical formulation as claimed in claim 1, the insulin analog being selected from the group consisting of Gly(A21), Arg(B31), Arg(B32) human insulin, Lys(B3), Glu(B29) human insulin, Asp(B28) human insulin, Lys(B28) Pro(B29) human insulin, Des(B30) human insulin and an insulin analog of the formula I
where
A0 is Lys or Arg;
A5 is Asp, Gln or Glu;
A15 is Asp, Glu or Gln;
A18 is Asp, Glu or Asn;
B-1 is Asp, Glu or an amino group;
B0 is Asp, Glu or a chemical bond;
B1 is Asp, Glu or Phe;
B2 is Asp, Glu or Val;
B3 is Asp, Glu or Asn;
B4 is Asp, Glu or Gln;
B29 is Lys or a chemical bond;
B30 is Thr or a chemical bond;
B31 is Arg, Lys or a chemical bond;
B32 is Arg-amide, Lys-amide or an amino group,
where two amino acid residues of the group containing A5, A15, A18, B-1, B0, B1, B2, B3, and B4, simultaneously and independently of one another, are Asp or Glu.

### Claim 4 (depends on 3)

The pharmaceutical formulation as claimed in claim 3, in which the insulin analog is selected from the group consisting of:
Arg (A0), His (A8), Glu (A5), Asp (A18), Gly (A21), Arg (B31), Arg (B32)-NH2 human insulin,
Arg (A0), His (A8), Glu (A5), Asp (A18), Gly (A21), Arg (B31), Lys (B32)-NH2 human insulin,
Arg (A0), His (A8), Glu (A15), Asp (A18), Gly (A21), Arg (B31), Arg (B32)-NH2 human insulin,
Arg (A0), His (A8), Glu (A15), Asp (A18), Gly (A21), Arg (B31), Lys (B32)-NH2 human insulin,
Arg (A0), His (A8), Glu(A5), Glu (A15), Gly (A21), Arg (B31), Arg (B32)-NH2human insulin,
Arg (A0), His (A8), Glu (A5), Glu (A15), Gly (A21), Arg (B31), Lys (B32)-NH2 human insulin,
Arg (A0), His(A8), Glu (A5), Gly (A21), Asp (B3), Arg (B31), Arg (B32)-NH2human insulin,
Arg (A0), His(A8), Glu (A5), Gly (A21), Asp (B3), Arg (B31), Lys (B32)-NH2human insulin,
Arg (A0), His (A8), Glu (A15), Gly (A21), Asp (B3), Arg (B31), Arg (B32)-NH2 human insulin,
Arg (A0), His (A8), Glu (A15), Gly (A21), Asp (B3), Arg (B31), Lys (B32)-NH2human insulin,
Arg (A0), His (A8), Asp (A18), Gly (A21), Asp (B3), Arg (B31), Arg (B32)-NH2 human insulin,
Arg (A0), His (A8), Asp (A18), Gly (A21), Asp (B3), Arg (B31), Lys (B32)-NH2 human insulin,
Arg (A0), His(A8), Gly (A21), Asp (B3), Glu (B4), Arg (B31), Arg (B32)-NH2 human insulin,
Arg (A0), His (A8), Gly (A21), Asp (B3), Glu (B4), Arg (B31), Lys (B32)-NH2 human insulin,
Arg (A0), His (A8), Glu (AS), Gly (A21), Glu (B4), Arg (B31), Arg (B32)-NH2human insulin,
Arg (A0), His (A8), Glu (A5), Gly (A21), Glu (B4), Arg (B31), Lys (B32)-NH2 human insulin,
Arg (A0), His (A8), Glu (A15), Gly (A21), Glu (B4), Arg (B31), Arg (B32)-NH2 human insulin,
Arg (A0), His (A8), Glu (A15), Gly (A21), Glu (B4), Arg (B31), Lys (B32)-NH2human insulin,
Arg (A0), His (A8), Asp (A18), Gly (A21), Glu (B4), Arg (B31), Arg (B32)-NH2 human insulin,
Arg (A0), His (A8), Asp (A18), Gly (A21), Glu (B4), Arg (B31), Lys (B32)-NH2 human insulin,
Arg (A0), His (A8), Glu (A5), Gly (A21), Glu (B0), Arg (B31), Arg (B32)-NH2 human insulin,
Arg (A0), His (A8), Glu (A5), Gly (A21), Glu (B0), Arg (B31), Lys (B32)-NH2 human insulin,
Arg (A0), His (A8), Glu (A15), Gly (A21), Glu (B0), Arg (B31), Arg (B32)-NH2 human insulin,
Arg (A0), His (A8), Glu (A15), Gly (A21), Glu (B0), Arg (B31), Lys (B32)-NH2 human insulin,
Arg (A0), His (A8), Asp (A18), Gly (A21), Glu (B0), Arg (B31), Arg (B32)-NH2 human insulin,
Arg (A0), His (A8), Asp (A18), Gly (A21), Glu (B0), Arg (B31), Lys (B32)-NH2 human insulin,
Arg (A0), His (A8), Glu (A5), Gly (A21), Asp (B1), Arg (B31), Arg (B32)-NH2 human insulin,
Arg (A0), His (A8), Glu (A5), Gly (A21), Asp (B1), Arg (B31), Lys (B32)-NH2 human insulin,
Arg (A0), His (A8), Glu (A 15), Gly (A21), Asp (B 1), Arg (B31), Arg(B32)-NH2 human insulin,
Arg (A0), His (A8), Glu (A15), Gly (A21), Asp (B1), Arg (B31), Lys (B32)-NH2human insulin,
Arg (A0), His (A8), Asp (A18), Gly (A21), Asp (B1), Arg (B31), Arg (B32)-NH2 human insulin,
Arg (A0), His (A8), Asp (A18), Gly (A21), Asp (B1), Arg (B31), Lys (B32)-NH2human insulin,
Arg (A0), His (A8), Gly (A21), Glu (B0), Asp (B1), Arg (B31), Arg (B32)-NH2 human insulin,
Arg (A0), His (A8), Gly (A21), Glu (B0), Asp (B1), Arg (B31), Lys (B32)-NH2human insulin,
Arg (A0), His (A8), Asp (A18), Gly (A21), Asp (B3), Arg (B30), Arg (B31)-NH2 human insulin, and
Arg (A0), His (A8), Asp (A18), Gly (A21), Asp (B3), Arg (B30), Lys (B31)-NH2 human insulin.

### Claim 5 (depends on 1)

The pharmaceutical formulation as claimed in claim 1, the insulin analog being selected from the group consisting of an insulin analog of the formula II
where
A-1 is Lys, Arg or an amino group;
A0 is Lys, Arg or a chemical bond;
A1 is Arg or Gly;
A5 is Asp, Glu or Gln;
A15 is Asp, Glu or Gln;
A18 is Asp, Glu or Asn;
A21 is Ala, Ser, Thr or Gly;
B-1 is Asp, Glu or an amino group;
B0 is Asp, Glu or a chemical bond;
B1 is Asp, Glu, Phe or a chemical bond;
B3 is Asp, Glu or Asn;
B4 is Asp, Glu or Gln;
B29 is Arg, Lys or an amino acid selected from the group containing the amino acids Phe, Ala, Thr, Ser, Val, Leu, Glu or Asp, or a chemical bond;
B30 is Thr or a chemical bond;
B31 is Arg, Lys or a chemical bond;
B32 is Arg-amide or Lys-amide,
where not more than one amino acid residue from the group containing A5, A15, A18, B-1, B0, B1, B2, B3 and B4, simultaneously and independently of one another, is Asp or Glu.

### Claim 6 (depends on 5)

The pharmaceutical formulation as claimed in claim 5, in which the insulin analog is selected from the group consisting of:
Arg (A-1), Arg (A0), Glu (A5), His (A8), Gly (A21), Arg (B30)-NH2 human insulin,
Arg (A-1), Arg (A0), Glu (A5), His (A8), Gly (A21), Lys (B30)-NH2 human insulin,
Arg (A-1), Arg (A0), Glu (A15), His (A8), Gly (A21), Arg (B30)-NH2 human
Arg (A-1), Arg (A0), Glu (A15), His (A8), Gly (A21), Lys (B30)-NH2 human insulin,
Arg (A-1), Arg (A0), Asp (A18), His (A8), Gly (A21), Arg (B30)-NH2human insulin,
Arg (A-1), Arg (A0), Asp (A18), His (A8), Gly (A21), Arg (B30)-NH2human insulin,
Arg (A-1), Arg (A0), His (A8), Gly (A21), Glu (B0), Arg (B30)-NH2human insulin,
Arg (A-1), Arg (A0), His (A8), Gly (A21), Glu (B0), Lys (B30)-NH2human insulin,
Arg (A-1), Arg (A0), His (A8), Gly (A21), Asp (B3), Arg (B30)-NH2 human insulin,
Arg (A-1), Arg (A0), His (A8), Gly (A21), Asp (B3), Lys (B30)-NH2human insulin,
Arg (A-1), Arg (A0), His (A8), Gly (A21), Glu (B4), Arg (B30)-NH2 human insulin,
Arg (A-1), Arg (A0), His (A8), Gly (A21), Glu (B4), Lys (B30)-NH2human insulin,
Arg (A0), His (A8), Gly (A21), Arg (B31), Arg (B32)-NH2 human insulin,
Arg (A0), His (A8), Gly (A21), Arg (B31), Lys (B32)-NH2 human insulin,
Arg (A0), Glu (A5), His (A8), Gly (A21), Arg (B31), Arg (B32)-NH2 human insulin,
Arg (A0), Glu (A5), His (A8), Gly (A21), Arg (B31), Lys (B32)-NH2 human insulin,
Arg (A0), Asp (A18), His (A8), Gly (A21), Arg (B31), Arg (B32)-NH2 human insulin,
Arg (A0), Asp (A18), His (A8), Gly (A21), Arg (B31), Lys (B32)-NH2 human insulin,
Arg (A0), Glu (A15), His (A8), Gly (A21), Arg (B31), Arg (B32)-NH2 human insulin,
Arg (A0), Glu (A15), His (A8), Gly (A21), Arg (B31), Lys (B32)-NH2 human insulin,
Arg (A0), His (A8), Gly (A21), Asp (B3), Arg (B31), Arg (B32)-NH2 human insulin,
Arg (A0), His (A8), Gly (A21), Asp (B3), Arg (B31), Lys (B32)-NH2 human insulin,
Arg (A0), His (A8), Gly (A21), Glu (B4), Arg (B31), Arg (B32)-NH2 human insulin,
Arg (A0), His (A8), Gly (A21), Glu (B4), Arg (B31), Lys (B32)-NH2 human insulin,
Arg (A0), His (A8), Gly (A21), Glu (B0), Arg (B31), Arg (B32)-NH2 human insulin,
Arg (A0), His (A8), Gly (A21), Glu (B0), Arg (B31), Lys (B32)-NH2 human insulin,
Arg (A0), His (A8), Gly (A21), Arg (B30)-NH2 human insulin,
Arg (A0), His (A8), Gly (A21), Lys (B30)-NH2 human insulin,
Arg (A-1), Arg (A0), His (A8), Gly (A21), Arg (B30)-NH2 human insulin,
Arg (A-1), Arg (A0), His (A8), Gly (A21), Lys (B30)-NH2 human insulin,
Arg (A0), Arg (A1), His (A8), Gly (A21), Arg (B30)-NH2 human insulin,
Arg (A0), Arg (A1), His (A8), Gly (A21), Lys (B30)-NH2 human insulin, and
His (A8), Gly (A21), Arg (B31), Arg (B32)-NH2 human insulin.

### Claim 7 (depends on 1)

The pharmaceutical formulation as claimed in claim 1, the insulin derivative being selected from the group consisting of B29-N-myristoyl-des(B30) human insulin, B29-N-palmitoyl-des(B30) human insulin, B29-N-myristoyl human insulin, B29-N-palmitoyl human insulin, B28-N-myristoyl LysB28ProB29 human insulin, B28-N-palmitoyl-LysB28ProB29 human insulin, B30-N-myristoyl-ThrB29LysB30 human insulin, B30-N-palmitoyl-ThrB29LysB30 human insulin, B29-N-(N-palmitoyl-Y-glutamyl)-des(B39) human insulin, B29-N—(N-lithocholyl-Y-glutamyl)-des(B30) human insulin, B29-N-(ω-carboxyheptadecanoyl)-des(B30) human insulin, and B29-N-(ω-carboxyheptadecanoyl) human insulin,

### Claim 8 (depends on 1)

The pharmaceutical formulation as claimed in claim 1, further comprising
0.001 to 0.2 mg/ml of zinc,
0.1 to 5.0 mg/ml of a preservative, and
5.0 to 100 mg/ml of an isotonicity agent, and
having a pH of 5 or less.

### Claim 9 (depends on 1)

The pharmaceutical formulation as claimed in claim 1 one, further comprising a preservative selected from the group consisting of phenol, m-cresol, chlorocresol, benzyl alcohol, and parabens.

### Claim 10 (depends on 1)

The pharmaceutical formulation as claimed in claim 1, further comprising an isotonicity agent selected from the group consisting of mannitol, sorbitol, lactose, dextrose, trehalose, sodium chloride, and glycerol.

### Claim 11 (depends on 1)

The pharmaceutical formulation as claimed in claim 1, having a pH in the range of pH 2.5-4.5.

### Claim 12 (depends on 1)

The pharmaceutical formulation as claimed in claim 1, having a pH in the range of pH 3.0-4.0.

### Claim 13 (depends on 1)

The pharmaceutical formulation as claimed in claim 1, having a pH in the region of pH 3.75.

### Claim 14 (depends on 1)

The pharmaceutical formulation as claimed in claim 1, wherein the insulin, insulin analog and/or insulin derivative is present in a concentration of 240-3000 nmol/ml.

### Claim 15 (depends on 1)

The pharmaceutical formulation as claimed in claim 1, further comprising glycerol at a concentration of 20 to 30 mg/ml.

### Claim 16 (depends on 1)

The pharmaceutical formulation as claimed in claim 1, further comprising glycerol at a concentration of 25 mg/ml.

### Claim 17 (depends on 1)

The pharmaceutical formulation as claimed in claim 1, further comprising m-cresol at a concentration of 1 to 3 mg/ml.

### Claim 18 (depends on 1)

The pharmaceutical formulation as claimed in claim 1, further comprising m-cresol at a concentration of 2 mg/ml.

### Claim 19 (depends on 1)

The pharmaceutical formulation as claimed in claim 1, further comprising zinc at a concentration of 0.01 or 0.03 or 0.08 mg/ml.

### Claim 20 (depends on 1)

The pharmaceutical formulation as claimed in claim 1, further comprising a glucagon-like peptide-1 (GLP 1) or an analog or derivative thereof, or exendin-3 and/or -4 or an analog or derivative thereof.

### Claim 21 (depends on 20)

The pharmaceutical formulation as claimed in claim 20, further comprising exendin-4.

### Claim 22 (depends on 20)

The pharmaceutical formulation as claimed in claim 20, in which an analog of exendin-4 is selected from the group consisting of
H-desPro36-exendin-4-Lys6-NH2,
H-des(Pro36,37)-exendin-4-Lys4-NH2 and
H-des(Pro36,37)-exendin-4-Lys5-NH2,
or a pharmacologically tolerable salt thereof.

### Claim 23 (depends on 20)

The pharmaceutical formulation as claimed in claim 20, in which an analog of exendin-4 is selected from the group consisting of
desPro36 [Asp28]exendin-4 (1-39),
desPro36 [IsoAsp28]exendin-4 (1-39),
desPro36 [Met(O)14, Asp28]exendin-4 (1-39),
desPro36 [Met(O)14, IsoAsp28]exendin-4 (1-39),
desPro36 [Trp(O2)25, Asp28]exendin-2 (1-39),
desPro36 [Trp(O2)25, IsoAsp28]exendin-2 (1-39),
desPro36 [Met(O)14Trp(O2)25, Asp28]exendin-4 (1-39) and
desPro36 [Met(O)14Trp(O2)25, IsoAsp28]exendin-4 (1-39),
or a pharmacologically tolerable salt thereof.

### Claim 24 (depends on 23)

The pharmaceutical formulation as claimed in claim 23, in which the peptide Lys6-NH2 is attached to the C-termini of the analogs of exendin-4.

### Claim 25 (depends on 20)

The pharmaceutical formulation as claimed in claim 20, in which an analog of exendin-4 is selected from the group consisting of
H-(Lys)6-des Pro36 [Asp28]exendin-4(1-39)-Lys6-NH2
des Asp28Pro36, Pro37, Pro38 exendin-4(1-39)-NH2,
H-(Lys)6-des Pro36, Pro37, Pro38 [Asp28]exendin-4(1-39)-NH2,
H-Asn-(Glu); des Pro36, Pro37, Pro38 [Asp28]exendin-4(1-39)-NH2,
des Pro36, Pro37, Pro38 [Asp28]exendin-4(1-39)-(Lys)6-NH2,
H-(Lys)6-des Pro36, Pro37, Pro38 [Asp28]exendin-4(1-39)-(Lys)6-NH2,
H-Asn-(Glu)5-des Pro36, Pro37, Pro38 [Asp28]exendin-4(1-39)-(Lys)6-NH2,
H-(Lys)6-des Pro36 [Trp(O2)25, Asp28]exendin-4(1-39)-Lys6-NH2,
H-des Asp28 Pro36, Pro37, Pro38 [Trp(O2)25]exendin-4(1-39)-NH2,
H-(Lys)6-des Pro36, Pro37, Pro38 [Trp(O2)25, Asp28]exendin-4(1-39)-NH2,
H-Asn-(Glu)5-des Pro36, Pro37, Pro38 [Trp(O2)25, Asp28]exendin-4(1-39)-NH2,
des Pro36, Pro37, Pro38 [Trp(O2)25, Asp28]exendin-4(1-39)-(Lys)6-NH2,
H-(Lys)6-des Pro36, Pro37, Pro38 [Trp(O2)25, Asp28]exendin-4(1-39)-(Lys)6-NH2,
H-Asn-(Glu)5-des Pro36, Pro37, Pro38 [Trp(O2)25, Asp28]exendin-4(1-39)-(Lys)6-NH2,
H-(Lys)6-des Pro36 [Met(O)14, Asp28]exendin-4(1-39)-Lys6-NH2,
des Met(O)14 Asp28 Pro36, Pro37, Pro38 exendin-4(1-39)-NH2,
H-(Lys)6-des Pro36, Pro37, Pro38 [Met(O)14, Asp28]exendin-4(1-39)-NH2,
H-Asn-(Glu)5-des Pro36, Pro37, Pro38 [Met(O)14, Asp28] exendin-4(1-39)-NH2,
des Pro36, Pro37, Pro38 [Met(O)14, Asp28]exendin-4(1-39)-(Lys)6-NH2,
H-(Lys)6-des Pro36, Pro37, Pro38 [Met(O)14, Asp28]exendin-4(1-39)-Lys6-NH2,
H-Asn-(Glu)5 des Pro36, Pro37, Pro38 [Met(O)14, Asp28] exendin-4(1-39)-(Lys)6-NH2,
H-(Lys)6-des Pro36 [Met(O)14, Trp(O2)25, Asp28]exendin-4(1-39)-Lys6-NH2,
des Asp28 Pro36, Pro37, Pro38 [Met(O)14, Trp(O2)21exendin-4(1-3 9)-NH2,
H-(Lys)6-des Pro36, Pro37, Pro38 [Met(O)14, Trp(O2)25, Asp28]exendin-4(1-39)-NH2,
H-Asn-(Glu)5-des Pro36, Pro37, Pro38 [Met(O)14, Asp28] exendin-4(1-39)-NH2,
des Pro36, Pro37, Pro38 [Met(O)14, Trp(O2)25, Asp28]exendin-4(1-39)-(Lys)6-NH2,
H-(Lys)6-des Pro36, Pro37, Pro38 [Met(O)14, Trp(O2)25, Asp28]exendin-4(1-39)-(Lys)6-NH2, and
H-Asn-(Glu)5-des Pro36, Pro37, Pro38 [Met(O)14, Trp(O2)25, Asp28] exendin-4(1-39)-(Lys)6-NH2,
or a pharmacologically tolerable salt thereof.

### Claim 26 (depends on 20)

The pharmaceutical formulation as claimed in claim 20, further comprising Arg34, Lys26 (Nε(γ-glutamyl(Nα-hexadecanoyl))) GLP-1 (7-37) [liraglutide] or a pharmacologically tolerable salt thereof.

### Claim 27 (depends on 1)

The pharmaceutical formulation as claimed in claim 1, comprising methionine in the concentration range of up to 10 mg/ml.

### Claim 28 (depends on 27)

The pharmaceutical formulation as claimed in claim 27, comprising methionine in the concentration range of up to 3 mg/ml.

### Claim 29 (depends on 1)

A process for preparing the pharmaceutical formulation as claimed in claim 1 comprising
(a) introducing the components into an aqueous solution and
(b) adjusting the pH.

### Claim 30 (depends on 1)

A method of treating diabetes mellitus in a patient in need thereof comprising administering to said patient a therapeutically effective amount of the aqueous pharmaceutical formulation of claim 1.

### Claim 31

(canceled)
